{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:17:56Z","timestamp":1759580276723},"reference-count":16,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Activation-induced deaminase initiates three different antibody diversification reactions: class switch recombination, somatic hypermutation (SHM), and gene conversion. We have shown that, in addition to antibody diversification, activation-induced deaminase can also initiate Burkitt's lymphoma\u2013like c-myc\/IgH translocations. However, distinct DNA damage- and oncogene-induced checkpoints operate in B cells to produce a normal intrachromosomal class switch recombination event or an aberrant interchromosomal fusion. These findings open the way to study the molecular pathways taking place at the early stages of malignant transformation. (Cancer Res 2006; 66(16): 7837-9)<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-0863","type":"journal-article","created":{"date-parts":[[2006,8,15]],"date-time":"2006-08-15T17:20:57Z","timestamp":1155662457000},"page":"7837-7839","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Switching on Chromosomal Translocations"],"prefix":"10.1158","volume":"66","author":[{"given":"Almudena R.","family":"Ramiro","sequence":"first","affiliation":[{"name":"1DNA Hypermutation Group, Spanish National Cancer Center, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[{"name":"2Laboratory of Molecular Immunology, The Rockefeller University;"},{"name":"3Howard Hughes Medical Institute, New York, New York; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre\u0301","family":"Nussenzweig","sequence":"additional","affiliation":[{"name":"4Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2006,8,15]]},"reference":[{"key":"2022061622122333500_B1","doi-asserted-by":"crossref","unstructured":"Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer\u20082005; 5: 251\u201362.","DOI":"10.1038\/nrc1589"},{"key":"2022061622122333500_B2","doi-asserted-by":"crossref","unstructured":"Chaudhuri J, Alt FW. Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat Rev Immunol\u20082004; 4: 541\u201352.","DOI":"10.1038\/nri1395"},{"key":"2022061622122333500_B3","doi-asserted-by":"crossref","unstructured":"Muramatsu M, Sankaranand VS, Anant S, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem\u20081999; 274: 18470\u20136.","DOI":"10.1074\/jbc.274.26.18470"},{"key":"2022061622122333500_B4","doi-asserted-by":"crossref","unstructured":"Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme [comment]. Cell\u20082000; 102: 553\u201363.","DOI":"10.1016\/S0092-8674(00)00078-7"},{"key":"2022061622122333500_B5","doi-asserted-by":"crossref","unstructured":"Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2) [comment]. Cell\u20082000; 102: 565\u201375.","DOI":"10.1016\/S0092-8674(00)00079-9"},{"key":"2022061622122333500_B6","doi-asserted-by":"crossref","unstructured":"Rada C, Di Noia JM, Neuberger MS. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A\/T-focused phase of somatic mutation. Mol Cell\u20082004; 16: 163\u201371.","DOI":"10.1016\/j.molcel.2004.10.011"},{"key":"2022061622122333500_B7","doi-asserted-by":"crossref","unstructured":"Kovalchuk AL, Kim JS, Park SS, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A\u20082002; 99: 1509\u201314.","DOI":"10.1073\/pnas.022643999"},{"key":"2022061622122333500_B8","doi-asserted-by":"crossref","unstructured":"Ramiro AR, Jankovic M, Eisenreich T, et al. AID is required for c-myc\/IgH chromosome translocations in vivo. Cell\u20082004; 118: 431\u20138.","DOI":"10.1016\/j.cell.2004.08.006"},{"key":"2022061622122333500_B9","doi-asserted-by":"crossref","unstructured":"Unniraman S, Zhou S, Schatz DG. Identification of an AID-independent pathway for chromosomal translocations between the IgH switch region and Myc. Nat Immunol\u20082004; 5: 1117\u201323.","DOI":"10.1038\/ni1127"},{"key":"2022061622122333500_B10","doi-asserted-by":"crossref","unstructured":"Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-IgH translocations. Nature\u20082006; 440: 105\u20139.","DOI":"10.1038\/nature04495"},{"key":"2022061622122333500_B11","doi-asserted-by":"crossref","unstructured":"Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair (Amst)\u20082004; 3: 959\u201367.","DOI":"10.1016\/j.dnarep.2004.03.024"},{"key":"2022061622122333500_B12","doi-asserted-by":"crossref","unstructured":"Franco S, Gostissa M, Zha S, et al. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol Cell\u20082006; 21: 201\u201314.","DOI":"10.1016\/j.molcel.2006.01.005"},{"key":"2022061622122333500_B13","doi-asserted-by":"crossref","unstructured":"Bassing CH, Suh H, Ferguson DO, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell\u20082003; 114: 359\u201370.","DOI":"10.1016\/S0092-8674(03)00566-X"},{"key":"2022061622122333500_B14","doi-asserted-by":"crossref","unstructured":"Ward I, Difilippantonio S, Minn K, et al. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol\u20082005; 22: 10079\u201386.","DOI":"10.1128\/MCB.25.22.10079-10086.2005"},{"key":"2022061622122333500_B15","doi-asserted-by":"crossref","unstructured":"Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature\u20082004; 432: 635\u20139.","DOI":"10.1038\/nature03147"},{"key":"2022061622122333500_B16","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature\u20082001; 412: 341\u20136.","DOI":"10.1038\/35085588"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/16\/7837\/2551713\/7837.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/66\/16\/7837\/2551713\/7837.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:13:07Z","timestamp":1655424787000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/66\/16\/7837\/525952\/Switching-on-Chromosomal-Translocations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,15]]},"references-count":16,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2006,8,15]]},"published-print":{"date-parts":[[2006,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-0863","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,15]]}}}